🇺🇸 FDA
Patent

US 10323061

Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof

granted A61KA61K31/58A61P

Quick answer

US patent 10323061 (Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof) held by Enanta Pharmaceuticals, Inc. expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/58, A61P, A61P1/16